Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid... Oncol Ther (2019) 7:131–139 https://doi.org/10.1007/s40487-019-00099-9 ORIGINAL RESEARCH Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients . . . . Marta Sese ´ Rosa Somoza Inmaculada Maestu Maria Martı ´n Ureste . . . Alfredo Sanchez Juan Felipe Cordoba Irene Sansano . . ´ ´ Griselda Venturas Santiago Ramon y Cajal Javier Hernandez-Losa Received: May 31, 2019 / Published online: August 19, 2019 The Author(s) 2019 development of new techniques for studying ABSTRACT tumor biomarkers in liquid biopsies, such as mutation analysis in cell-free DNA (cfDNA). Introduction: Precision medicine has revolu- cfDNA analysis can accurately determine tumor tionized the understanding and treatment of progression and prognosis and more effectively cancer by identifying subsets of patients who identify appropriate targeted therapies. How- are amenable to specific treatments according ever, cfDNA is vulnerable, particularly during to their molecular characteristics, as exempli- plasma sample shipping. fied by epidermal growth factor receptor (EGFR) Objective: We compared the cell- and DNA- mutations in non-small cell lung cancer stabilizing properties of cell-free DNA blood (NSCLC). Although tissue biopsy is the gold collection tubes (BCTs) with those of the tradi- standard for determining molecular alterations tional shipping http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/validation-of-cell-free-dna-collection-tubes-for-determination-of-egfr-k64ExK4jGK
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00099-9
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:131–139 https://doi.org/10.1007/s40487-019-00099-9 ORIGINAL RESEARCH Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients . . . . Marta Sese ´ Rosa Somoza Inmaculada Maestu Maria Martı ´n Ureste . . . Alfredo Sanchez Juan Felipe Cordoba Irene Sansano . . ´ ´ Griselda Venturas Santiago Ramon y Cajal Javier Hernandez-Losa Received: May 31, 2019 / Published online: August 19, 2019 The Author(s) 2019 development of new techniques for studying ABSTRACT tumor biomarkers in liquid biopsies, such as mutation analysis in cell-free DNA (cfDNA). Introduction: Precision medicine has revolu- cfDNA analysis can accurately determine tumor tionized the understanding and treatment of progression and prognosis and more effectively cancer by identifying subsets of patients who identify appropriate targeted therapies. How- are amenable to specific treatments according ever, cfDNA is vulnerable, particularly during to their molecular characteristics, as exempli- plasma sample shipping. fied by epidermal growth factor receptor (EGFR) Objective: We compared the cell- and DNA- mutations in non-small cell lung cancer stabilizing properties of cell-free DNA blood (NSCLC). Although tissue biopsy is the gold collection tubes (BCTs) with those of the tradi- standard for determining molecular alterations tional shipping

Journal

Oncology and Therapy – Springer Journals

Published: Aug 19, 2019

References

  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok, TS; Wu, YL; Thongprasert, S; Yang, CH; Chu, DT; Saijo, N
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ; Bell, DW; Sordella, R; Gurubhagavatula, S; Okimoto, RA; Brannigan, BW
  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, R; Carcereny, E; Gervais, R; Vergnenegre, A; Massuti, B; Felip, E
  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
    Yang, JC; Wu, YL; Schuler, M; Sebastian, M; Popat, S; Yamamoto, N
  • AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
    Janne, PA; Yang, JC; Kim, DW; Planchard, D; Ohe, Y; Ramalingam, SS
  • AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
    Gil-Bazo, I; Rolfo, C
  • Rociletinib in EGFR-mutated non-small-cell lung cancer
    Sequist, LV; Rolfe, L; Allen, AR
  • Cancer genomics: diversity and disparity across ethnicity and geography
    Tan, DS; Mok, TS; Rebbeck, TR
  • Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
    Lee, DH
  • The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
    Wang, S; Yu, B; Ng, CC; Mercorella, B; Selinger, CI; O’Toole, SA
  • The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment
    Ofiara, LM; Navasakulpong, A; Ezer, N; Gonzalez, AV
  • Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790 M-positive cancers with a third-generation EGFR inhibitor
    Piotrowska, Z; Niederst, MJ; Karlovich, CA; Wakelee, HA; Neal, JW; Mino-Kenudson, M
  • Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
    Zhang, Y; Chang, L; Yang, Y; Fang, W; Guan, Y; Wu, A
  • Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small cell lung cancer
    Wan, R; Wang, Z; Lee, JJ; Wang, S; Li, Q; Tang, F
  • High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients
    Jing, CW; Wang, Z; Cao, HX; Ma, R; Wu, JZ
  • Liquid biopsy: monitoring cancer-genetics in the blood
    Crowley, E; Nicolantonio, F; Loupakis, F; Bardelli, A
  • Liquid biopsy and lung cancer
    Pisapia, P; Malapelle, U; Troncone, G
  • Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
    Merker, JD; Oxnard, GR; Compton, C; Diehn, M; Hurley, P; Lazar, AJ
  • Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy
    Alix-Panabieres, C; Pantel, K
  • Liquid biopsies: genotyping circulating tumor DNA
    Diaz, LA; Bardelli, A
  • Circulating tumor DNA as a liquid biopsy for cancer
    Heitzer, E; Ulz, P; Geigl, JB
  • Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring
    Luo, W; Rao, M; Qu, J; Luo, D
  • Application of plasma genotyping technologies in non-small cell lung cancer: a practical review
    Sacher, AG; Komatsubara, KM; Oxnard, GR
  • Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA)
    Lim, M; Kim, CJ; Sunkara, V; Kim, MH; Cho, YK
  • The effect of preservative and temperature on the analysis of circulating tumor DNA
    Parpart-Li, S; Bartlett, B; Popoli, M; Adleff, V; Tucker, L; Steinberg, R
  • Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer
    Malapelle, U; Sirera, R; Jantus-Lewintre, E; Reclusa, P; Calabuig-Farinas, S; Blasco, A
  • Liquid biopsy preservation solutions for standardized pre-analytical workflows-venous whole blood and plasma
    Grolz, D; Hauch, S; Schlumpberger, M; Guenther, K; Voss, T; Sprenger-Haussels, M
  • A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device
    Norton, SE; Luna, KK; Lechner, JM; Qin, J; Fernando, MR
  • A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR
    Norton, SE; Lechner, JM; Williams, T; Fernando, MR
  • A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage
    Fernando, MR; Chen, K; Norton, S; Krzyzanowski, G; Bourne, D; Hunsley, B
  • Evaluation of Streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma
    Warton, K; Yuwono, NL; Cowley, MJ; McCabe, MJ; So, A; Ford, CE
  • Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial
    Benlloch, S; Botero, ML; Beltran-Alamillo, J; Mayo, C; Gimenez-Capitan, A; Aguirre, I
  • Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols
    Ahlborn, LB; Madsen, M; Jonson, L; Nielsen, FC; Lassen, U; Yde, CW
  • Performance of Streck cfDNA blood collection tubes for liquid biopsy testing
    Medina Diaz, I; Nocon, A; Mehnert, DH; Fredebohm, J; Diehl, F; Holtrup, F